数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

   CYCC
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

股本结构

单位：万股
公告日期 2024-01-19 2024-03-21 2023-12-26 2023-12-12 2023-08-10 2022-11-10
证券总股本 131.83 105.89 100.85 84.00 1264.28 1253.92
普通股本 131.83 105.89 100.85 84.00 1264.28 1253.92
优先股 未披露 45.45 未披露 未披露 57.33 57.33
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2024-01-17 2023-12-31 2023-12-26 2023-12-18 2023-06-30 2022-09-30
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2024-01-19 131.83 未披露 定期报告 2024-01-17
2024-03-21 105.89 45.45
更多>>
From December 31, 2022 to December 31, 2023 Conversion of series B Preferred stock Reclassification of redeemable common stock Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct Offering, net of expenses Stock-based compensation
2023-12-31
2023-12-26 100.85 未披露
更多>>
Common stock offered 168,500 shares by the company
2023-12-26
2023-12-12 84.00 未披露
更多>>
Cyclacel Pharmaceuticals, Inc. announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (“Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on Friday, December 15, 2023.
2023-12-18
2023-08-10 1264.28 57.33 定期报告 2023-06-30
2022-11-10 1253.92 57.33
更多>>
From June 30, 2022 to September 30, 2022 Issue of common stock on At Market issuance sales agreement, net of expenses Reclassification of redeemable common stock
2022-09-30
2022-08-11 1253.92 未披露 定期报告 2022-08-10
2022-08-11 1135.03 57.33
更多>>
From March 31, 2022 to June 30, 2022 Issue of common stock on At Market issuance sales agreement, net of expenses Stock-based awards
2022-06-30
2022-05-12 999.50 未披露 定期报告 2022-05-09
2022-05-12 999.31 57.33 定期报告 2022-03-31
2022-03-30 999.31 83.73
更多>>
From December 31, 2020 to December 31, 2021 Issue of common stock and associated warrants on underwritten offering, net of expenses Issue of common stock in At Market Issuance sales agreement, net of expenses Warrant & stock option exercises
2021-12-31
2021-11-12 997.51 未披露 定期报告 2021-11-10
2021-11-12 979.77 57.33
更多>>
From June 30, 2021 to September 30, 2021 Issue of common stock on At Market issuance sales agreement, net of expenses
2021-09-30
2021-05-14 923.41 57.33
更多>>
From December 31, 2020 To March 31, 2021 Issuance of common stock in underwritten offering, net of issuance costs Warrant Exercises
2021-03-31
2021-03-16 805.40 未披露
更多>>
1.Common stock offered by the company 1,807,143 shares. 2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 6,246,896 shares of common stock outstanding as of December 31, 2020.
2021-03-16
2021-03-01 710.37 未披露 定期报告 2021-02-24
2021-03-01 624.69 33.55
更多>>
From December 31, 2019 to December 31, 2020 Issue of common stock, preferred stock, pre-funded warrants and warrants on equity financing, net of expenses Warrant exercises
2020-12-31
2020-12-22 534.99 23.77
更多>>
1.The company is offering 485,912 Common Shares and 237,745 Preferred Shares to the Investor. 2.Unless the company indicate otherwise, all information in this prospectus supplement is based on 4,863,984 shares of common stock outstanding as of September 30, 2020.
2020-12-22
2020-08-13 486.40 33.55
更多>>
from March 31, 2020 to June 30, 2020 Issue of common stock, pre-funded warrants and warrants on equity financing, net of expenses
2020-06-30
2020-05-12 486.00 未披露 定期报告 2020-05-11
2020-05-12 473.99 33.53 定期报告 2020-05-01
2020-04-24 277.00 未披露
更多>>
Cyclacel Pharmaceuticals, Inc. today announced the closing of its previously announced public offering of (i) 4,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof). The offering is expected to close on April 23, 2020, subject to customary closing conditions.
2020-04-23
2020-04-14 86.00 未披露
更多>>
The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. Trading of the Company’s common stock on The NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Wednesday, April 15, 2020, under the existing trading symbol “CYCC” and under a new CUSIP number 23254L603.The reverse stock split reduces the number of shares of the Company’s common stock outstanding from approximately 17.2 million pre-reverse split shares to approximately 860,000 post-reverse split shares.
2020-04-15
2019-05-14 1720.00 33.55
更多>>
From December 31, 2018 to March 31, 2019 Issue of common stock on At Market Issuance sales agreement
2019-03-31
2019-03-28 1720.00 未披露
更多>>
During the first quarter of 2019, the Company sold a further 4.7 million shares under the Sales Agreement with Wainwright for gross proceeds of approximately $4.3 million. The Company has now reached the maximum aggregate offering price and there will be no further sale of shares under the Sales Agreement.
2019-03-28
2019-03-28 1249.74 33.55
更多>>
From December 31, 2017 to December 31, 2018 At Market Issuance sales agreement
2018-12-31
2018-11-13 1249.74 未披露 定期报告 2018-11-09
2018-03-30 1199.74 33.55
更多>>
From December 31, 2016 to December 31, 2017 Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses Series A Preferred stock conversions Warrant exercise Issue of common stock on At Market Issuance sales agreement
2017-12-31
2017-11-13 1190.45 未披露 定期报告 2017-11-13
2017-11-13 1169.70 33.53 定期报告 2017-09-30
2017-08-10 1140.04 未披露
更多>>
Subsequent to the closing of the offering, holders of 7,613 (86%) shares of the Series A Preferred Stock elected to convert their shares into 3,806,500 shares of common stock. Following such conversions, 11,400,447 shares of common stock and 1,259 (14%) shares of Series A Preferred Stock remain outstanding as of August 8, 2017.
2017-08-08
2017-05-26 443.99 33.53 定期报告 2017-05-19
2017-05-12 427.29 未披露 定期报告 2017-05-12
2017-04-12 427.20 33.53 定期报告 2017-04-05
2017-05-12 427.29 33.53 定期报告 2017-03-31
2017-03-31 427.20 未披露 定期报告 2017-03-24
2017-03-31 296.52 33.53
更多>>
from December 31, 2015 to December 31, 2016 Issue of common stock on At Market Issuance sales agreement On May 26, 2016, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twelve reverse stock split of the Company’s shares of common stock. The reverse stock split became effective at 5:00 p.m., Eastern Time, on May 27, 2016, and the Company’s common stock will trade on the NASDAQ Capital Market on a post-split basis at the open of business on May 31, 2016.
2016-12-31
2016-11-14 425.12 33.53 定期报告 2016-09-30
2016-08-11 311.84 未披露 定期报告 2016-08-09
2016-08-11 300.72 33.53 定期报告 2016-06-30
2016-06-03 307.93 33.53 定期报告 2016-06-02
2016-05-27 300.63 未披露
更多>>
On May 26, 2016, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twelve reverse stock split of the Company’s shares of common stock. The reverse stock split became effective at 5:00 p.m., Eastern Time, on May 27, 2016, and the Company’s common stock will trade on the NASDAQ Capital Market on a post-split basis at the open of business on May 31, 2016.
2016-05-31
2016-04-29 3607.57 33.53 定期报告 2016-04-27
2016-03-29 3558.25 33.53
更多>>
from December 31, 2014 to December 31, 2015 Issue of common stock for cash on registered direct offering, net of expenses Issue of common stock upon draw down of Committed Equity Finance Facility Issue of common stock on share purchase agreement Stock-based awards vested
2015-12-31
2015-11-12 3470.29 33.53 定期报告 2015-09-30
2015-08-12 3470.29 未披露 定期报告 2015-08-11
2015-08-11 3438.85 33.53 定期报告 2015-06-30
2015-05-12 3438.85 33.53 定期报告 2015-03-31
2015-03-31 3438.85 未披露 定期报告 2015-03-27
2015-03-31 2319.95 33.53
更多>>
From December 31,2013 to December 31,2014 Issue of common stock for cash on registered direct offering, net of expenses Issue of common stock on share purchase agreement Stock-based awards exercised
2014-12-31
2014-11-12 2297.65 未披露 定期报告 2014-11-11
2014-08-12 2267.65 33.53 定期报告 2014-06-30
2014-05-13 2267.65 未披露 定期报告 2014-05-12
2014-04-02 1981.93 33.53 定期报告 2014-03-26
2014-03-26 1981.93 未披露 定期报告 2014-03-24
2014-03-26 1936.93 33.53
更多>>
From December 31,2012 to December 31,2013 Issue of common stock for cash in an underwritten public offering, net of expenses Issue of common stock on share purchase agreement Stock issued to employees in lieu of cash bonus Preferred stock conversion
2013-12-31
2013-11-14 1869.17 33.53 定期报告 2013-09-30
2013-08-14 1771.51 42.07 定期报告 2013-06-30
2013-05-13 1088.18 未披露 定期报告 2013-05-13
2013-04-08 1083.18 42.09 定期报告 2013-04-01
2013-05-13 1088.18 42.07 定期报告 2013-03-31
2013-04-01 1083.18 未披露 定期报告 2013-03-29
2013-01-11 931.80 86.12 定期报告 2013-01-07
2013-04-01 868.65 121.31
更多>>
from December 31, 2011 to December 31, 2012 Issue of common stock on private placement, net of expenses Issue of common stock on share purchase agreement Stock-based awards exercised Implemented a 1-for-7 reverse stock split of shares of common stock
2012-12-31
2012-11-16 843.48 未披露 定期报告 2012-11-14
2012-11-13 843.43 121.31
更多>>
Implemented a 1-for-7 reverse stock split of shares of common stock
2012-09-30
2012-08-14 5900.80 未披露 定期报告 2012-08-13
2012-08-14 5900.12 121.31 定期报告 2012-06-30
2012-05-15 5900.33 未披露 定期报告 2012-05-15
2012-05-15 5899.34 121.31 定期报告 2012-03-31
2012-03-30 5900.17 未披露 定期报告 2012-03-29
2012-03-30 5422.05 121.31
更多>>
from December 31, 2010 to December 31, 2011 Issue of common stock for cash on registered direct offering, net of expenses Stock-based awards exercised
2011-12-31
2011-11-14 5422.88 未披露 定期报告 2011-11-14
2011-11-14 5421.26 121.31 定期报告 2011-09-30
2011-08-12 5422.41 未披露 定期报告 2011-08-12
2011-08-11 4658.72 121.31 定期报告 2011-06-30
2011-05-16 4660.18 未披露 定期报告 2011-05-16
2011-05-12 4657.79 121.31 定期报告 2011-03-31
2011-03-31 4659.87 未披露 定期报告 2011-03-30
2011-03-31 4656.49 121.31
更多>>
Preferred stock conversions Issue of common stock for cash on registered direct offering, net of expenses Issue of common stock upon draw down of Committed Equity Finance Facility Warrant exercise Issue of common stock on private placement, net of expenses Stock-based awards exercised
2010-12-31
2010-11-12 4656.08 未披露 定期报告 2010-11-11
2010-11-12 3823.60 121.31 定期报告 2010-09-30
2010-08-13 3695.05 未披露 定期报告 2010-08-12
2010-08-13 3692.03 121.31 定期报告 2010-06-30
2010-05-19 3687.24 未披露 定期报告 2010-05-18
2010-05-19 3541.13 192.34 定期报告 2010-03-31
From December 31, 2022 to December 31, 2023 Conversion of series B Preferred stock Reclassification of redeemable common stock Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Registered Direct Offering, net of expenses Stock-based compensation
Common stock offered 168,500 shares by the company
Cyclacel Pharmaceuticals, Inc. announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (“Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on Friday, December 15, 2023.
From June 30, 2022 to September 30, 2022 Issue of common stock on At Market issuance sales agreement, net of expenses Reclassification of redeemable common stock
From March 31, 2022 to June 30, 2022 Issue of common stock on At Market issuance sales agreement, net of expenses Stock-based awards
From December 31, 2020 to December 31, 2021 Issue of common stock and associated warrants on underwritten offering, net of expenses Issue of common stock in At Market Issuance sales agreement, net of expenses Warrant & stock option exercises
From June 30, 2021 to September 30, 2021 Issue of common stock on At Market issuance sales agreement, net of expenses
From December 31, 2020 To March 31, 2021 Issuance of common stock in underwritten offering, net of issuance costs Warrant Exercises
1.Common stock offered by the company 1,807,143 shares. 2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 6,246,896 shares of common stock outstanding as of December 31, 2020.
From December 31, 2019 to December 31, 2020 Issue of common stock, preferred stock, pre-funded warrants and warrants on equity financing, net of expenses Warrant exercises
1.The company is offering 485,912 Common Shares and 237,745 Preferred Shares to the Investor. 2.Unless the company indicate otherwise, all information in this prospectus supplement is based on 4,863,984 shares of common stock outstanding as of September 30, 2020.
from March 31, 2020 to June 30, 2020 Issue of common stock, pre-funded warrants and warrants on equity financing, net of expenses
Cyclacel Pharmaceuticals, Inc. today announced the closing of its previously announced public offering of (i) 4,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof). The offering is expected to close on April 23, 2020, subject to customary closing conditions.
The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. Trading of the Company’s common stock on The NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Wednesday, April 15, 2020, under the existing trading symbol “CYCC” and under a new CUSIP number 23254L603.The reverse stock split reduces the number of shares of the Company’s common stock outstanding from approximately 17.2 million pre-reverse split shares to approximately 860,000 post-reverse split shares.
From December 31, 2018 to March 31, 2019 Issue of common stock on At Market Issuance sales agreement
During the first quarter of 2019, the Company sold a further 4.7 million shares under the Sales Agreement with Wainwright for gross proceeds of approximately $4.3 million. The Company has now reached the maximum aggregate offering price and there will be no further sale of shares under the Sales Agreement.
From December 31, 2017 to December 31, 2018 At Market Issuance sales agreement
From December 31, 2016 to December 31, 2017 Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses Series A Preferred stock conversions Warrant exercise Issue of common stock on At Market Issuance sales agreement
Subsequent to the closing of the offering, holders of 7,613 (86%) shares of the Series A Preferred Stock elected to convert their shares into 3,806,500 shares of common stock. Following such conversions, 11,400,447 shares of common stock and 1,259 (14%) shares of Series A Preferred Stock remain outstanding as of August 8, 2017.
from December 31, 2015 to December 31, 2016 Issue of common stock on At Market Issuance sales agreement On May 26, 2016, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twelve reverse stock split of the Company’s shares of common stock. The reverse stock split became effective at 5:00 p.m., Eastern Time, on May 27, 2016, and the Company’s common stock will trade on the NASDAQ Capital Market on a post-split basis at the open of business on May 31, 2016.
On May 26, 2016, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twelve reverse stock split of the Company’s shares of common stock. The reverse stock split became effective at 5:00 p.m., Eastern Time, on May 27, 2016, and the Company’s common stock will trade on the NASDAQ Capital Market on a post-split basis at the open of business on May 31, 2016.
from December 31, 2014 to December 31, 2015 Issue of common stock for cash on registered direct offering, net of expenses Issue of common stock upon draw down of Committed Equity Finance Facility Issue of common stock on share purchase agreement Stock-based awards vested
From December 31,2013 to December 31,2014 Issue of common stock for cash on registered direct offering, net of expenses Issue of common stock on share purchase agreement Stock-based awards exercised
From December 31,2012 to December 31,2013 Issue of common stock for cash in an underwritten public offering, net of expenses Issue of common stock on share purchase agreement Stock issued to employees in lieu of cash bonus Preferred stock conversion
from December 31, 2011 to December 31, 2012 Issue of common stock on private placement, net of expenses Issue of common stock on share purchase agreement Stock-based awards exercised Implemented a 1-for-7 reverse stock split of shares of common stock
Implemented a 1-for-7 reverse stock split of shares of common stock
from December 31, 2010 to December 31, 2011 Issue of common stock for cash on registered direct offering, net of expenses Stock-based awards exercised
Preferred stock conversions Issue of common stock for cash on registered direct offering, net of expenses Issue of common stock upon draw down of Committed Equity Finance Facility Warrant exercise Issue of common stock on private placement, net of expenses Stock-based awards exercised